Irish NASH drug will also be investigated for Major Lung Diseases

23/05/2016 - 2 minutes

DS Biopharma was already studying one of its bioactive lipids for non-alcoholic steatohepatitis (NASH). The candidate will now also target chronic obstructive pulmonary disease (COPD).

ds_biopharma_ds102_lung_copd_nashHeadquartered in Dublin (Ireland), DS Biopharma is working on new medicines for medical unmet needs, such as fibrosis. This development of fibrous tissue can affect the lungs, liver or heart.

DS has developed a bioactive lipid technology platform, which includes semi-synthetic fatty acids and has already received an European patent.

These lipids are crucial in the pathways of several conditions including metabolic disorders of the liver and fibrotic disorders.

While there is no known effective way of ‘persuade’ the body to produce more of these lipids, DS has synthesised several of these compounds – which could be delivered topically or orally.

One of its candidates is DS102, which was already being studied for in non-alcoholic steatohepatitis (NASH). This liver disease is on the rise and has attracted plenty of investor’s attention.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member